H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3 from $3.50 and keeps a Buy rating on the shares following the Q4 report. The firm says the Tecelra launch is gaining momentum.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Therapeutics: Balancing Positive Momentum with Strategic Pauses – A Hold Rating Analysis
- Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
- Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook
- Adaptimmune price target lowered to $1.40 from $3.15 at Scotiabank
- Adaptimmune price target lowered to $1.50 from $2 at Wells Fargo
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue